IMER - Institute for Medical Education and Research

SURVEY: Nursing Perspectives on Survivorship, Distress Screening, and Patient Navigation http://conta.cc/TTcpnE

Nursing Perspectives on Survivorship, Distress Screening, and Patient Navigation Please help us better understand oncology nursing perspectives on the current status of treatment and survivorship care planning, distress screening, and patient navigation processes at your institution. The intent is to help develop national initiatives to overcome perceived shortfalls in the deliv...

Less than 10 days until Immuno-Oncology 1/2 Day CME Conference - Register Now! http://conta.cc/Xo1Qt8

Immuno-Oncology: A Colloquium on the State of the Science for Oncology Clinicians Register Now! The incidence of melanoma is growing rapidly in the United States. Although no new agents have been approved to treat the disease in more than 10 years, recent clinical research into immunomodulatory approaches, such as antibodies, small molecule inhibitors, and vaccines, promises a major paradigm s...

Celgene's Abraxane Gets FDA Approval to Treat Non-Small Cell Lung Cancer

One-Third of Men With A**l Cancer Have HIV, Study Finds

http://health.usnews.com/health-news/news/articles/2012/10/05/one-third-of-men-with-anal-cancer-have-hiv-study-finds

One-Third of Men With A**l Cancer Have HIV, Study Finds - US News and World Report Gay males among those at higher risk of the rare cancer, U.S. government researchers say

Ovarian Cancer News:
Discovery leads to new hope against ovarian cancer
http://news.usc.edu/ #!/article/42119/discovery-leads-to-new-hope-against-ovarian-cancer/

IMER CE-Accredited Activities:
Read Highlights of the July semi-annual GOG Meeting from Dr. Deborah Armstrong and receive credit! http://bit.ly/R4FNTs

Discovery leads to new hope against ovarian cancer | USC News Philanthropist, actor and businesswoman Michele Dedeaux Engemann ’68 was elected to the USC Board of Trustees on Oct. 3.

Renal Cell Carcinoma:-
COMPARZ trial: pazopanib and sunitinib similarly effective in first line treatment of metastatic RCC.
INTORSECT trial: Temsirolimus does not demonstrate superiority in survival over sorafenib in second-line treatment .

http://www.esmo.org/no_cache/view-news.html?tx_ttnews%5Btt_news%5D=1653&tx_ttnews%5BbackPid%5D=585&cHash=d823c017fe

View News - European Society for Medical Oncology (ESMO) European Society for Medical Oncology

Pomalidomide FDA review as a treatment for MM shifts from Nov 2012 to Feb 2013.
http://www.businessweek.com/ap/2012-10-03/celgene-says-fda-panel-wont-review-pomalidomide

Celgene says FDA panel won't review pomalidomide SUMMIT, N.J. (AP) — Celgene Corp. said Wednesday that a Food and Drug Administration panel will not review its multiple myeloma drug pomalidomide in November.

GI Societies Issue New Colonoscopy Surveillance Guidelines
"Patients at average risk of colorectal cancer who have a clean colonoscopy do not need to repeat the test for 10 years." http://www.gastro.org/news/articles/2012/10/01/gi-societies-issue-new-colonoscopy-surveillance-guidelines

Article • American Gastroenterological Association (AGA)

Nab-paclitaxel (Abraxane) met its primary endpoint of delaying the growth of tumors in patients with advanced melanoma.

http://www.thestreet.com/story/11724846/1/celgene-surprises-with-melanoma-drug-study-victory.html?puc=yahoo&cm_ven=YAHOO

Celgene Surprises With Melanoma Drug Study Victory - TheStreet Celgene's Abraxane delays tumor growth in patients with advanced melanoma.

Regorafenib approved for advanced CRC
http://www.businessweek.com/news/2012-10-01/bayer-s-stivarga-helps-colorectal-cancer-patients-live-longer

Do you have questions regarding immunotherapy treatment for cancer? Post your questions here and our Immuno-oncology panel will address them on Saturday's webcast http://bit.ly/OgROch

If You Missed New York City, Then Check Out Chicago on LIVE WEBCAST! This Saturday 29th September, from 8:00-12:15.
Immuno-Oncology Half-Day CME/CE/CPE Conference; earn up to 4 credits!

CLICK HERE TO REGISTER NOW --> http://bit.ly/OgROch
When you register, send us your questions for the panel discussion.